Navigation Links
Nobel laureate James Watson publishes novel hypothesis on curing late-stage cancers
Date:1/8/2013

Cold Spring Harbor, NY "Although mortality from many cancers has been steadily falling, particularly those of the blood [i.e., leukemias], the more important statistic may be that so many epithelial cancers (carcinomas) and effectively all mesenchymal cancers (sarcomas) remain largely incurable."

With these words as preface, Nobel laureate James D. Watson, Ph.D., in a newly published paper that he regards "among my most important work since the double helix," sets forth a novel hypothesis regarding the role of oxidants and antioxidants in cancers that are currently incurable, notably in late-stage metastatic cancers.

At the heart of his thesis are the group of molecules that scientists call reactive oxygen species, or ROS. Noting their fundamental two-sidedness, Watson calls ROS "a positive force for life" because of their role in apoptosis an internal program that highly stressed cells use to commit suicide. It's one of the key mechanisms that have arisen through eons of evolution to weed out biological dysfunction that poses a threat to the survival of organisms. On the other hand, ROS are also well understood indeed are notorious "for their ability to irreversibly damage key proteins and nucleic acid molecules [e.g., DNA and RNA]."

When they're not needed to curb wayward or out of control cells, which is to say under normal circumstances, ROS are constantly being neutralized by anti-oxidative proteins. We are often urged to eat foods rich in antioxidants such as blueberries; but, if Watson is correct about the role of ROS and antioxidants in late-stage cancer, as he writes in his new paper, "blueberries best be eaten because they taste good, not because their consumption will lead to less cancer."

Understanding why this might be so why antioxidants can in late-stage cancers actually promote cancer progression -- is central to Watson's paper, which appears online January 9 in Open Biology, a journal of Great Britain's Royal Society.

He proposes that the cell-killing ability of currently used anti-cancer therapies toxic chemotherapeutic agents such as Taxol as well as radiation treatment is mainly due to the action of ROS to induce apoptosis, or programmed cell death. This would explain "why cancers that become resistant to chemotherapeutic control become equally resistant to radiotherapy." The common feature would be their common dependence upon a ROS-mediated cell-killing mechanism.

Watson, who is Chancellor Emeritus of Cold Spring Harbor Laboratory, then takes up the case of cancer cells largely driven by mutant proteins such as RAS and MYC. These, he notes, are often hardest to get to respond to treatment. He suggests this could be due to their high levels of ROS-destroying antioxidants. He cites recent research showing up-regulation of a gene transcription factor called Nrf2 when cells proliferate as well as when oncogenes such as RAS, MYC and RAF are active. Nrf2 controls the synthesis of antioxidants, and "this makes sense because we want antioxidants present when DNA functions to make more of itself," Watson writes.

In calling for "a much faster timetable for developing anti-metastatic drugs," the Nobel laureate wants those reading his new paper to consider a proposition he considers grossly underexplored: "Unless we can find ways of reducing antioxidant levels, late-stage cancer 10 years from now will be as incurable as it is today."


'/>"/>

Contact: Peter Tarr
tarr@cshl.edu
516-367-8455
Cold Spring Harbor Laboratory
Source:Eurekalert

Related medicine news :

1. Sanford-Burnhams Erkki Ruoslahti named to Thomson Reuters Nobel Prize watch list
2. Nobel laureate to keynote international pharmaceutical conference at URI
3. NAI Fellows Robert Langer, Leroy Hood and Member James Wynne receive US National Medals
4. Before Skyfall: 46 years of violence in James Bond movies
5. James George, MD: 2012 ASH Wallace H. Coulter Award for Lifetime Achievement in Hematology
6. Medical Tourism: Uncharted Territory for Patients James Goldberg, Author of the American Medical Money Machine, Is Offering a New Consulting Service to Medical Patients Considering “Medical Tourism” Treatment
7. Same-Sex Couples Might File Tax Refund Claims According to Watson CPA Group
8. Few Hours Left for Charitable Tax Deductions According to Watson CPA Group
9. Astro Clairvoyant Norah Guide for Premium Astrology Publishes New Blog Series on 2013 Predictions
10. Atlanta Surgeon for LASIK Eye Surgery Publishes Study on Website About Car Technology to Monitor Drowsiness
11. Zane Benefits Publishes "The Crisis in Employee Health Benefits 1999-2012"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... , ... “Journey to the Light: The Quest for Happiness and Love. . ... to finding herself. “Journey to the Light: The Quest for Happiness and Love. ... writer of newsletters, manuals, and articles, who has recently decided to expand her literary ...
(Date:7/23/2017)... (PRWEB) , ... July 23, 2017 , ... A ... in St. Louis, and led by the Minneapolis Veterans Administration Health Care System overwhelmingly ... of the disease offers very few benefits. , In the cases involved with ...
(Date:7/23/2017)... ... 23, 2017 , ... Technology is making it easier for ... tools are helping patients become more actively involved in their care and maintaining ... survey, released today by the American Hospital Association’s (AHA) Health Forum. , According ...
(Date:7/23/2017)... ... July 23, 2017 , ... Viora Ltd., a ... US Patent No. 9,038,640 by the United States Patent and Trademark Office. The ... combination of Switching, Vacuum, and Cooling mechanisms to further increase the efficacy and ...
(Date:7/21/2017)... ... July 21, 2017 , ... "As a doctor of lung medicine ... catheters available on the market," said an inventor from Center Valley, Pa. "My idea ... the patient." , He developed the patent-pending PLEURAL SAFE-t-STAT CATHETER KIT to offer an ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/10/2017)... , July 10, 2017 The Institute for ... methods, is the recipient of a VITROCELL® inhalation exposure ... International Science Consortium. The device, which is designed to ... expose human lung cells to airborne test materials in ... use the VITROCELL® system for testing combustible tobacco products, ...
(Date:7/5/2017)... 5, 2017 Wolfmet 3D  printed tungsten collimator manufactured by ... and manufacturing combine to progress molecular radiotherapy imaging. ... are unable to accurately quantify the radiation absorbed by those ... the success of this radiotherapy treatment has been available — ... ...
Breaking Medicine Technology: